JP2020502213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502213A5 JP2020502213A5 JP2019533489A JP2019533489A JP2020502213A5 JP 2020502213 A5 JP2020502213 A5 JP 2020502213A5 JP 2019533489 A JP2019533489 A JP 2019533489A JP 2019533489 A JP2019533489 A JP 2019533489A JP 2020502213 A5 JP2020502213 A5 JP 2020502213A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- alkyl
- phenyl
- cyclopropyl
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 50
- 125000001424 substituent group Chemical group 0.000 claims 45
- -1 pyrazole-4-yl Chemical group 0.000 claims 40
- 208000002193 Pain Diseases 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 22
- 201000010099 disease Diseases 0.000 claims 19
- 229910052731 fluorine Inorganic materials 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 16
- 125000004432 carbon atom Chemical group C* 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 125000005842 heteroatom Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 13
- 208000011580 syndromic disease Diseases 0.000 claims 12
- 229910052801 chlorine Inorganic materials 0.000 claims 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- 239000005711 Benzoic acid Substances 0.000 claims 9
- 235000010233 benzoic acid Nutrition 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 208000024891 symptom Diseases 0.000 claims 9
- 206010035664 Pneumonia Diseases 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 5
- 201000009273 Endometriosis Diseases 0.000 claims 5
- 206010030113 Oedema Diseases 0.000 claims 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 201000008482 osteoarthritis Diseases 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 201000005569 Gout Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010020853 Hypertonic bladder Diseases 0.000 claims 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 3
- 206010033645 Pancreatitis Diseases 0.000 claims 3
- 206010033799 Paralysis Diseases 0.000 claims 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000020629 overactive bladder Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 2
- 229920000742 Cotton Polymers 0.000 claims 2
- 206010011796 Cystitis interstitial Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010061979 Genital pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 241000208125 Nicotiana Species 0.000 claims 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 2
- 208000000450 Pelvic Pain Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- 239000003610 charcoal Substances 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 206010013990 dysuria Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000002175 menstrual effect Effects 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- SPLLGXCKZJCOGA-UHFFFAOYSA-N 2-(1-benzothiophen-2-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound S1C(=CC2=C1C=CC=C2)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F SPLLGXCKZJCOGA-UHFFFAOYSA-N 0.000 claims 1
- ZWELQKMKGRLXGD-UHFFFAOYSA-N 2-(1-cyclobutyl-3-fluoropyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=C(C(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F)F ZWELQKMKGRLXGD-UHFFFAOYSA-N 0.000 claims 1
- SLZUUKYITSTWIN-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-3-fluoro-5-[[1-(2-fluoro-4-methylphenyl)cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)C)F SLZUUKYITSTWIN-UHFFFAOYSA-N 0.000 claims 1
- IUUOOSSNXCCWSG-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-3-fluoro-5-[[1-(5-fluoropyridin-2-yl)cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=NC=C(C=C1)F IUUOOSSNXCCWSG-UHFFFAOYSA-N 0.000 claims 1
- LHYDLFVHSXREDW-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F LHYDLFVHSXREDW-UHFFFAOYSA-N 0.000 claims 1
- WGJDSFNBLJOHPM-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F WGJDSFNBLJOHPM-UHFFFAOYSA-N 0.000 claims 1
- XJDQTSXXOYYQPM-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-3-fluoro-5-[[1-[3-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=CC(=C(C=C1)C(F)(F)F)F XJDQTSXXOYYQPM-UHFFFAOYSA-N 0.000 claims 1
- FMLUTSJYVCQXGM-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-3-fluoro-5-[[1-[4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=CC=C(C=C1)OC(F)(F)F FMLUTSJYVCQXGM-UHFFFAOYSA-N 0.000 claims 1
- INGVSMJXHRAHKR-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-3-fluoro-5-[[1-[4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=CC=C(C=C1)C(F)(F)F INGVSMJXHRAHKR-UHFFFAOYSA-N 0.000 claims 1
- OTKADLJLSKIEFF-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-5-[[1-(2,4-difluorophenyl)cyclopropanecarbonyl]amino]-3-fluorobenzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)F)F OTKADLJLSKIEFF-UHFFFAOYSA-N 0.000 claims 1
- CDTASRIWCPXZDF-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-5-[[1-(3,4-difluorophenyl)cyclopropanecarbonyl]amino]-3-fluorobenzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=CC(=C(C=C1)F)F CDTASRIWCPXZDF-UHFFFAOYSA-N 0.000 claims 1
- SMHPXSBGGKDSSM-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]-3-methylbenzoic acid Chemical compound Cc1cc(NC(=O)C2(CC2)c2ccc(OC(F)(F)F)cc2F)cc(C(O)=O)c1-c1cnn(c1)C1CCC1 SMHPXSBGGKDSSM-UHFFFAOYSA-N 0.000 claims 1
- XKTGTXHJMCTLNP-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F XKTGTXHJMCTLNP-UHFFFAOYSA-N 0.000 claims 1
- AJWVHJYOBHSPFW-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]-3-methylbenzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1C)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F AJWVHJYOBHSPFW-UHFFFAOYSA-N 0.000 claims 1
- DFQFSWDEFZCQLH-UHFFFAOYSA-N 2-(1-cyclobutylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F DFQFSWDEFZCQLH-UHFFFAOYSA-N 0.000 claims 1
- BTXJPCQSTIYZTA-UHFFFAOYSA-N 2-(1-cyclohexylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCCCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F BTXJPCQSTIYZTA-UHFFFAOYSA-N 0.000 claims 1
- QLXDHHAUENNNDY-UHFFFAOYSA-N 2-(1-cyclohexylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCCCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F QLXDHHAUENNNDY-UHFFFAOYSA-N 0.000 claims 1
- XDYVLUWLMVALAZ-UHFFFAOYSA-N 2-(1-cyclopentylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCCC1)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F XDYVLUWLMVALAZ-UHFFFAOYSA-N 0.000 claims 1
- KIZISVSWHICRJX-UHFFFAOYSA-N 2-(1-ethylpyrazol-4-yl)-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F KIZISVSWHICRJX-UHFFFAOYSA-N 0.000 claims 1
- GGVADENEQQARBQ-UHFFFAOYSA-N 2-(1-ethylpyrazol-4-yl)-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F GGVADENEQQARBQ-UHFFFAOYSA-N 0.000 claims 1
- OCLFSJBHPXRQSO-UHFFFAOYSA-N 2-(1-ethylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound CCn1cc(cn1)-c1ccc(NC(=O)C2(CC2)c2ccc(OC(F)(F)F)cc2F)cc1C(O)=O OCLFSJBHPXRQSO-UHFFFAOYSA-N 0.000 claims 1
- QXCCTXLJOKMTSM-UHFFFAOYSA-N 2-(1-ethylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F QXCCTXLJOKMTSM-UHFFFAOYSA-N 0.000 claims 1
- VIXHTTPNSKOSBV-UHFFFAOYSA-N 2-(1-tert-butylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)(C)(C)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F VIXHTTPNSKOSBV-UHFFFAOYSA-N 0.000 claims 1
- YUHZGIZLRDBNGP-UHFFFAOYSA-N 2-(1-tert-butylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)(C)(C)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F YUHZGIZLRDBNGP-UHFFFAOYSA-N 0.000 claims 1
- OBMPTFTWQVGVHK-UHFFFAOYSA-N 2-(2-cyclobutyl-1,3-thiazol-5-yl)-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)C=1SC(=CN=1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F OBMPTFTWQVGVHK-UHFFFAOYSA-N 0.000 claims 1
- UFCFKJIKEUMGFX-UHFFFAOYSA-N 2-(2-cyclobutyl-1,3-thiazol-5-yl)-5-[[1-(2-fluoro-4-methylphenyl)cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)C=1SC(=CN=1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C)F UFCFKJIKEUMGFX-UHFFFAOYSA-N 0.000 claims 1
- XYZXYEVRQBAKGA-UHFFFAOYSA-N 2-(2-cyclobutyl-1,3-thiazol-5-yl)-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)C=1SC(=CN=1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F XYZXYEVRQBAKGA-UHFFFAOYSA-N 0.000 claims 1
- LALBKFAYHBLPRK-UHFFFAOYSA-N 2-(2-cyclobutyl-1,3-thiazol-5-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCC1)C=1SC(=CN=1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F LALBKFAYHBLPRK-UHFFFAOYSA-N 0.000 claims 1
- FYCZPQCWSRXAEG-UHFFFAOYSA-N 2-(2-cyclopentyl-1,3-thiazol-5-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CCCC1)C=1SC(=CN=1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F FYCZPQCWSRXAEG-UHFFFAOYSA-N 0.000 claims 1
- NKDLQJSRJGPMAN-UHFFFAOYSA-N 2-(4-tert-butylimidazol-1-yl)-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)(C)(C)C=1N=CN(C=1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F NKDLQJSRJGPMAN-UHFFFAOYSA-N 0.000 claims 1
- ITJNQLASJHLBFQ-UHFFFAOYSA-N 2-(4-tert-butylimidazol-1-yl)-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)(C)(C)C=1N=CN(C=1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F ITJNQLASJHLBFQ-UHFFFAOYSA-N 0.000 claims 1
- CNQSTNMARXBHIF-UHFFFAOYSA-N 2-(6-ethoxypyridin-3-yl)-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)OC1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F CNQSTNMARXBHIF-UHFFFAOYSA-N 0.000 claims 1
- ACGFEBLWOAAMSD-UHFFFAOYSA-N 2-(6-ethoxypyridin-3-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)OC1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F ACGFEBLWOAAMSD-UHFFFAOYSA-N 0.000 claims 1
- GBDSHNGDMLTYTC-UHFFFAOYSA-N 2-(6-ethylpyridin-3-yl)-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)C1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F GBDSHNGDMLTYTC-UHFFFAOYSA-N 0.000 claims 1
- XRPAYFRNOWBMHJ-UHFFFAOYSA-N 2-(6-ethylpyridin-3-yl)-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)C1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F XRPAYFRNOWBMHJ-UHFFFAOYSA-N 0.000 claims 1
- OWSOOCFQTAMTRH-UHFFFAOYSA-N 2-(6-ethylpyridin-3-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C(C)C1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F OWSOOCFQTAMTRH-UHFFFAOYSA-N 0.000 claims 1
- JXTXIWVZORMYSW-UHFFFAOYSA-N 2-[1-(2,2-dimethylpropyl)pyrazol-4-yl]-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound CC(CN1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F)(C)C JXTXIWVZORMYSW-UHFFFAOYSA-N 0.000 claims 1
- CSMHWLYSPOPOAV-UHFFFAOYSA-N 2-[1-(2,2-dimethylpropyl)pyrazol-4-yl]-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound CC(CN1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F)(C)C CSMHWLYSPOPOAV-UHFFFAOYSA-N 0.000 claims 1
- KPZAGCPZZHGMTL-UHFFFAOYSA-N 2-[1-(cyclobutylmethyl)pyrazol-4-yl]-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound OC(=O)C1=C(C=CC(NC(=O)C2(CC2)C2=C(F)C=C(OC(F)(F)F)C=C2)=C1)C1=CN(CC2CCC2)N=C1 KPZAGCPZZHGMTL-UHFFFAOYSA-N 0.000 claims 1
- MCQQSWPZVKKJNZ-UHFFFAOYSA-N 2-[1-(cyclobutylmethyl)pyrazol-4-yl]-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound OC(=O)C1=C(C=CC(NC(=O)C2(CC2)C2=C(F)C=C(C=C2)C(F)(F)F)=C1)C1=CN(CC2CCC2)N=C1 MCQQSWPZVKKJNZ-UHFFFAOYSA-N 0.000 claims 1
- ZYBBFSHQRRPSAV-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)pyrazol-4-yl]-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound OC(=O)C1=C(C2=CN(CC3CC3)N=C2)C(F)=CC(NC(=O)C2(CC2)C2=C(F)C=C(OC(F)(F)F)C=C2)=C1 ZYBBFSHQRRPSAV-UHFFFAOYSA-N 0.000 claims 1
- JWVLWTTZAXLMMK-UHFFFAOYSA-N 2-[1-(cyclopropylmethyl)pyrazol-4-yl]-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound OC(=O)C1=C(C2=CN(CC3CC3)N=C2)C(F)=CC(NC(=O)C2(CC2)C2=C(F)C=C(C=C2)C(F)(F)F)=C1 JWVLWTTZAXLMMK-UHFFFAOYSA-N 0.000 claims 1
- FAWYZGHAODSGMT-AWEZNQCLSA-N 2-[1-[(1S)-1-cyclopropylethyl]pyrazol-4-yl]-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C1(CC1)[C@H](C)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F FAWYZGHAODSGMT-AWEZNQCLSA-N 0.000 claims 1
- WPNCYDCPXAFTAG-CQSZACIVSA-N 2-[1-[(2R)-butan-2-yl]pyrazol-4-yl]-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C[C@H](CC)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F WPNCYDCPXAFTAG-CQSZACIVSA-N 0.000 claims 1
- PDFHMQKQOIFYIJ-AWEZNQCLSA-N 2-[1-[(2S)-butan-2-yl]pyrazol-4-yl]-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound C[C@@H](CC)N1N=CC(=C1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F PDFHMQKQOIFYIJ-AWEZNQCLSA-N 0.000 claims 1
- DEBRTGIYBVRSAV-UHFFFAOYSA-N 2-[6-(1,1-difluoropropyl)pyridin-3-yl]-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound FC(CC)(F)C1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F DEBRTGIYBVRSAV-UHFFFAOYSA-N 0.000 claims 1
- PVBLWJNWYADJOE-UHFFFAOYSA-N 2-[6-(1,1-difluoropropyl)pyridin-3-yl]-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound FC(CC)(F)C1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F PVBLWJNWYADJOE-UHFFFAOYSA-N 0.000 claims 1
- VURZQVUNWCGXPW-UHFFFAOYSA-N 2-[6-(1,1-difluoropropyl)pyridin-3-yl]-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound FC(CC)(F)C1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F VURZQVUNWCGXPW-UHFFFAOYSA-N 0.000 claims 1
- RFRFRTJDHNWZEI-UHFFFAOYSA-N 2-[6-(1,1-difluoropropyl)pyridin-3-yl]-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound FC(CC)(F)C1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F RFRFRTJDHNWZEI-UHFFFAOYSA-N 0.000 claims 1
- NWONYPVGLIJGCV-UHFFFAOYSA-N 2-[6-(difluoromethyl)pyridin-3-yl]-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound FC(C1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F)F NWONYPVGLIJGCV-UHFFFAOYSA-N 0.000 claims 1
- DKWUKFNDRSQFMF-UHFFFAOYSA-N 2-[6-(difluoromethyl)pyridin-3-yl]-3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound FC(C1=CC=C(C=N1)C1=C(C(=O)O)C=C(C=C1F)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F)F DKWUKFNDRSQFMF-UHFFFAOYSA-N 0.000 claims 1
- YTMTTYDTLBFCRU-UHFFFAOYSA-N 3-chloro-2-(1-cyclobutylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound ClC=1C(=C(C(=O)O)C=C(C=1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F)C=1C=NN(C=1)C1CCC1 YTMTTYDTLBFCRU-UHFFFAOYSA-N 0.000 claims 1
- SRFKHESUWQNZBQ-UHFFFAOYSA-N 3-chloro-2-(1-cyclobutylpyrazol-4-yl)-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound ClC=1C(=C(C(=O)O)C=C(C=1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F)C=1C=NN(C=1)C1CCC1 SRFKHESUWQNZBQ-UHFFFAOYSA-N 0.000 claims 1
- NOTXFEUYPGEODC-UHFFFAOYSA-N 3-chloro-2-[6-(1,1-difluoropropyl)pyridin-3-yl]-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound ClC=1C(=C(C(=O)O)C=C(C=1)NC(=O)C1(CC1)C1=C(C=C(C=C1)OC(F)(F)F)F)C=1C=NC(=CC=1)C(CC)(F)F NOTXFEUYPGEODC-UHFFFAOYSA-N 0.000 claims 1
- CKIGZFUXQVIXST-UHFFFAOYSA-N 3-chloro-2-[6-(1,1-difluoropropyl)pyridin-3-yl]-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]benzoic acid Chemical compound ClC=1C(=C(C(=O)O)C=C(C=1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F)C=1C=NC(=CC=1)C(CC)(F)F CKIGZFUXQVIXST-UHFFFAOYSA-N 0.000 claims 1
- ABBDQACFIYCXKK-UHFFFAOYSA-N 3-fluoro-5-[[1-(2-fluoro-4-methylphenyl)cyclopropanecarbonyl]amino]-2-(1-propan-2-ylpyrazol-4-yl)benzoic acid Chemical compound FC=1C(=C(C(=O)O)C=C(C=1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C)F)C=1C=NN(C=1)C(C)C ABBDQACFIYCXKK-UHFFFAOYSA-N 0.000 claims 1
- CBDYMHUHKQYMDD-UHFFFAOYSA-N 3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]-2-(1-methylindazol-6-yl)benzoic acid Chemical compound Cn1ncc2ccc(cc12)-c1c(F)cc(NC(=O)C2(CC2)c2ccc(OC(F)(F)F)cc2F)cc1C(O)=O CBDYMHUHKQYMDD-UHFFFAOYSA-N 0.000 claims 1
- PIBQZIJQJPHVRJ-UHFFFAOYSA-N 3-fluoro-5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]-2-(6-methylpyridin-3-yl)benzoic acid Chemical compound FC=1C(=C(C(=O)O)C=C(C=1)NC(=O)C1(CC1)C1=C(C=C(C=C1)C(F)(F)F)F)C=1C=NC(=CC=1)C PIBQZIJQJPHVRJ-UHFFFAOYSA-N 0.000 claims 1
- OGCZNGPOUJLJCT-UHFFFAOYSA-N 5-[[1-(4-chloro-2-fluorophenyl)cyclopropanecarbonyl]amino]-2-(1-cyclobutylpyrazol-4-yl)-3-fluorobenzoic acid Chemical compound ClC1=CC(=C(C=C1)C1(CC1)C(=O)NC=1C=C(C(=C(C(=O)O)C=1)C=1C=NN(C=1)C1CCC1)F)F OGCZNGPOUJLJCT-UHFFFAOYSA-N 0.000 claims 1
- UUEQUQAJIQOUDR-UHFFFAOYSA-N 5-[[1-(4-chloro-2-fluorophenyl)cyclopropanecarbonyl]amino]-2-(1-cyclobutylpyrazol-4-yl)benzoic acid Chemical compound ClC1=CC(=C(C=C1)C1(CC1)C(=O)NC=1C=CC(=C(C(=O)O)C=1)C=1C=NN(C=1)C1CCC1)F UUEQUQAJIQOUDR-UHFFFAOYSA-N 0.000 claims 1
- XCZKFLRZKIEHIB-UHFFFAOYSA-N 5-[[1-(4-chloro-2-fluorophenyl)cyclopropanecarbonyl]amino]-2-(2-cyclobutyl-1,3-thiazol-5-yl)benzoic acid Chemical compound ClC1=CC(=C(C=C1)C1(CC1)C(=O)NC=1C=CC(=C(C(=O)O)C=1)C1=CN=C(S1)C1CCC1)F XCZKFLRZKIEHIB-UHFFFAOYSA-N 0.000 claims 1
- ZEFKBQBXQRFWMC-UHFFFAOYSA-N 5-[[1-(4-chloro-2-fluorophenyl)cyclopropanecarbonyl]amino]-3-fluoro-2-(1-propan-2-ylpyrazol-4-yl)benzoic acid Chemical compound ClC1=CC(=C(C=C1)C1(CC1)C(=O)NC=1C=C(C(=C(C(=O)O)C=1)C=1C=NN(C=1)C(C)C)F)F ZEFKBQBXQRFWMC-UHFFFAOYSA-N 0.000 claims 1
- DAMBPDIDCWMFOD-UHFFFAOYSA-N 5-[[1-(4-chloro-3-fluorophenyl)cyclopropanecarbonyl]amino]-2-(1-cyclobutylpyrazol-4-yl)benzoic acid Chemical compound ClC1=C(C=C(C=C1)C1(CC1)C(=O)NC=1C=CC(=C(C(=O)O)C=1)C=1C=NN(C=1)C1CCC1)F DAMBPDIDCWMFOD-UHFFFAOYSA-N 0.000 claims 1
- CKZLOVZWZXTQPG-UHFFFAOYSA-N 5-[[1-(4-chlorophenyl)cyclopropanecarbonyl]amino]-2-(1-cyclobutylpyrazol-4-yl)-3-fluorobenzoic acid Chemical compound ClC1=CC=C(C=C1)C1(CC1)C(=O)NC=1C=C(C(=C(C(=O)O)C=1)C=1C=NN(C=1)C1CCC1)F CKZLOVZWZXTQPG-UHFFFAOYSA-N 0.000 claims 1
- VGGFHQDZGAKXHX-UHFFFAOYSA-N 5-[[1-(5-chloro-2-fluorophenyl)cyclopropanecarbonyl]amino]-2-(1-cyclobutylpyrazol-4-yl)benzoic acid Chemical compound ClC=1C=CC(=C(C=1)C1(CC1)C(=O)NC=1C=CC(=C(C(=O)O)C=1)C=1C=NN(C=1)C1CCC1)F VGGFHQDZGAKXHX-UHFFFAOYSA-N 0.000 claims 1
- QJCPSGAZXDPCNQ-UHFFFAOYSA-N 5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]-2-(1-propan-2-ylpyrazol-4-yl)benzoic acid Chemical compound FC1=C(C=CC(=C1)OC(F)(F)F)C1(CC1)C(=O)NC=1C=CC(=C(C(=O)O)C=1)C=1C=NN(C=1)C(C)C QJCPSGAZXDPCNQ-UHFFFAOYSA-N 0.000 claims 1
- QIRRHAKQRFODBR-UHFFFAOYSA-N 5-[[1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]-2-[1-(2-methylpropyl)pyrazol-4-yl]benzoic acid Chemical compound FC1=C(C=CC(=C1)OC(F)(F)F)C1(CC1)C(=O)NC=1C=CC(=C(C(=O)O)C=1)C=1C=NN(C=1)CC(C)C QIRRHAKQRFODBR-UHFFFAOYSA-N 0.000 claims 1
- GSGIFEHXJCBYMQ-UHFFFAOYSA-N 5-[[1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropanecarbonyl]amino]-2-(1-propan-2-ylpyrazol-4-yl)benzoic acid Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)C1(CC1)C(=O)NC=1C=CC(=C(C(=O)O)C=1)C=1C=NN(C=1)C(C)C GSGIFEHXJCBYMQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000018652 Closed Head injury Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000004483 Dyspareunia Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 206010051235 Madarosis Diseases 0.000 claims 1
- 208000008763 Mercury poisoning Diseases 0.000 claims 1
- 206010027439 Metal poisoning Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000029549 Muscle injury Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029174 Nerve compression Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038419 Renal colic Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000007613 Shoulder Pain Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 206010072005 Spinal pain Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000010040 Sprains and Strains Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046823 Uterine spasm Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 210000003423 ankle Anatomy 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000002682 general surgery Methods 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 201000010659 intrinsic asthma Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000005518 mononeuropathy Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000019382 nerve compression syndrome Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000007892 occupational asthma Diseases 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000020049 trigeminal nerve disease Diseases 0.000 claims 1
- 208000036722 ulnar neuropathy Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000005186 women's health Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16206750 | 2016-12-23 | ||
| EP16206750.8 | 2016-12-23 | ||
| PCT/EP2017/083290 WO2018114786A1 (en) | 2016-12-23 | 2017-12-18 | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502213A JP2020502213A (ja) | 2020-01-23 |
| JP2020502213A5 true JP2020502213A5 (enExample) | 2021-02-04 |
| JP7161474B2 JP7161474B2 (ja) | 2022-10-26 |
Family
ID=57609782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533489A Active JP7161474B2 (ja) | 2016-12-23 | 2017-12-18 | ブラジキニンｂ１受容体の拮抗薬としてのカルボン酸芳香族アミド類 |
Country Status (38)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12023319B2 (en) * | 2016-12-23 | 2024-07-02 | Bayer Pharma Aktiengesellschaft | Carboxylic acid aromatic amides |
| TW202317519A (zh) | 2021-07-05 | 2023-05-01 | 德商拜耳廠股份有限公司 | 2-(1-環丁基-1h-吡唑-4-基)-5-[({1-[2-氟-4-(三氟甲基)-苯基]環丙基}羰基)胺基]苯甲酸之膽鹼鹽 |
| CN118475567A (zh) | 2021-08-11 | 2024-08-09 | 西藏海思科制药有限公司 | 一种杂环衍生物及其组合物和药学上的应用 |
| WO2023054626A1 (ja) * | 2021-09-30 | 2023-04-06 | 住友ファーマ株式会社 | シクロプロパンアミド誘導体 |
| CN114591338B (zh) * | 2022-03-31 | 2023-05-09 | 苏州欧康维视生物科技有限公司 | 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624155A1 (de) * | 1996-06-18 | 1998-01-08 | Hoechst Ag | Substituierte Benzoesäurederivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| CA2473778A1 (en) | 2002-02-08 | 2003-08-14 | Merck & Co., Inc. | N-biphenylmethyl aminocycloalkanecarboxamide derivatives |
| US20070124389A1 (en) | 2005-11-28 | 2007-05-31 | Lucent Technologies Inc. | Anti-spam application storage system |
| CA2635760C (en) | 2005-12-28 | 2014-07-15 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| AR068509A1 (es) | 2007-09-19 | 2009-11-18 | Jerini Ag | Antagosnistas del receptor de bradiquinina b1 |
| TW201217312A (en) | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
| HUP1000598A2 (en) * | 2010-11-05 | 2012-09-28 | Richter Gedeon Nyrt | Indole derivatives |
| US9062013B2 (en) * | 2011-02-02 | 2015-06-23 | Bionomics Limited | Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| WO2012112567A1 (en) | 2011-02-15 | 2012-08-23 | Georgetown University | Small molecule inhibitors of agbl2 |
| SG11201408327XA (en) * | 2012-06-15 | 2015-02-27 | Taisho Pharmaceutical Co Ltd | Heteroaromatic methyl cyclic amine derivative |
| PT3436461T (pt) | 2016-03-28 | 2024-01-23 | Incyte Corp | Compostos de pirrolotriazina como inibidores de tam |
| RU2755728C2 (ru) | 2016-12-23 | 2021-09-20 | Хайдельберг Фарма Ресёрч Гмбх | Новый конъюгат аманитина |
-
2017
- 2017-12-17 JO JOP/2019/0156A patent/JOP20190156B1/ar active
- 2017-12-18 HU HUE17826197A patent/HUE057973T2/hu unknown
- 2017-12-18 CN CN202210782842.1A patent/CN115137726B/zh active Active
- 2017-12-18 UA UAA201908005A patent/UA124244C2/uk unknown
- 2017-12-18 EP EP17826197.0A patent/EP3558960B1/en active Active
- 2017-12-18 MA MA47082A patent/MA47082B1/fr unknown
- 2017-12-18 HR HRP20220132TT patent/HRP20220132T1/hr unknown
- 2017-12-18 KR KR1020197021028A patent/KR102542790B1/ko active Active
- 2017-12-18 AU AU2017381629A patent/AU2017381629B2/en active Active
- 2017-12-18 EA EA201991490A patent/EA039447B1/ru unknown
- 2017-12-18 PT PT178261970T patent/PT3558960T/pt unknown
- 2017-12-18 MX MX2019007647A patent/MX378164B/es unknown
- 2017-12-18 CA CA3047815A patent/CA3047815A1/en active Pending
- 2017-12-18 PH PH1/2019/501424A patent/PH12019501424B1/en unknown
- 2017-12-18 SG SG10202012217QA patent/SG10202012217QA/en unknown
- 2017-12-18 BR BR112019012920A patent/BR112019012920A2/pt not_active Application Discontinuation
- 2017-12-18 JP JP2019533489A patent/JP7161474B2/ja active Active
- 2017-12-18 CU CU2019000062A patent/CU24528B1/es unknown
- 2017-12-18 LT LTEPPCT/EP2017/083290T patent/LT3558960T/lt unknown
- 2017-12-18 CN CN202210783168.9A patent/CN115068468B/zh active Active
- 2017-12-18 DK DK17826197.0T patent/DK3558960T3/da active
- 2017-12-18 CN CN201780087290.XA patent/CN110325523B/zh active Active
- 2017-12-18 ES ES17826197T patent/ES2908638T3/es active Active
- 2017-12-18 US US16/472,118 patent/US11905270B2/en active Active
- 2017-12-18 SI SI201731071T patent/SI3558960T1/sl unknown
- 2017-12-18 WO PCT/EP2017/083290 patent/WO2018114786A1/en not_active Ceased
- 2017-12-18 CN CN202210782834.7A patent/CN115073421B/zh active Active
- 2017-12-18 TW TW106144384A patent/TWI762542B/zh active
- 2017-12-18 CR CR20190298A patent/CR20190298A/es unknown
- 2017-12-18 PL PL17826197T patent/PL3558960T3/pl unknown
- 2017-12-18 RS RS20220249A patent/RS62999B1/sr unknown
- 2017-12-18 PE PE2019001306A patent/PE20191249A1/es unknown
- 2017-12-18 GE GEAP201715141A patent/GEP20227378B/en unknown
- 2017-12-21 UY UY0001037538A patent/UY37538A/es active IP Right Grant
- 2017-12-22 AR ARP170103640A patent/AR110432A1/es unknown
-
2019
- 2019-06-17 IL IL267440A patent/IL267440B/en unknown
- 2019-06-21 EC ECSENADI201944591A patent/ECSP19044591A/es unknown
- 2019-06-21 NI NI201900063A patent/NI201900063A/es unknown
- 2019-06-21 CL CL2019001746A patent/CL2019001746A1/es unknown
- 2019-06-21 CO CONC2019/0006652A patent/CO2019006652A2/es unknown
-
2022
- 2022-03-15 CY CY20221100216T patent/CY1125085T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502213A5 (enExample) | ||
| KR102858043B1 (ko) | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 | |
| CN101611013B (zh) | 作为5-ht2a血清素受体调节剂用于治疗与其相关病症的吡唑衍生物 | |
| TWI583681B (zh) | 胺基嘧啶基化合物 | |
| JP7258903B2 (ja) | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 | |
| JP2010523623A (ja) | Ｐ２ｘ７調節因子としてのピラゾール誘導体 | |
| JP2018519323A5 (enExample) | ||
| JP2017508766A5 (enExample) | ||
| JP2004524301A5 (enExample) | ||
| WO2001074771A1 (en) | Pyrrole-2,5-dione derivatives for the treatment of diabetes | |
| RU2009117475A (ru) | Соединения, модулирующие активность c-fms и/или c-kit, и их применения | |
| EP3331863A1 (en) | Novel compounds as ror gamma modulators | |
| JP2014532640A5 (enExample) | ||
| HRP20220132T1 (hr) | Aromatski amidi karboksilne kiseline kao antagonisti bradikininskog b1 receptora | |
| JP2010526781A (ja) | ジアシルグリセロールｏ−アシル転移酵素１型酵素の阻害剤 | |
| JP2011513367A5 (enExample) | ||
| EP1991536A2 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
| JP5552121B2 (ja) | ロイコトリエン産生のインドリジン阻害剤 | |
| JP2013509376A5 (enExample) | ||
| JP2021098692A5 (enExample) | ||
| JP5526777B2 (ja) | 二環式複素環化合物 | |
| JP2008503447A5 (enExample) | ||
| JP2007526311A (ja) | ブラジキニンアンタゴニストとしてのアミノシクロプロパンカルボキサミド誘導体 | |
| KR20130097748A (ko) | 신규한 ｔｒｐｖ３ 조절제 | |
| US7790754B2 (en) | Alpha-hydroxy amides as bradykinin antagonists or inverse agonists |